Brokers Offer Predictions for XENE FY2025 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Chardan Capital issued their FY2025 earnings per share estimates for Xenon Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 19th. Chardan Capital analyst K. Nakae anticipates that the biopharmaceutical company will post earnings of ($4.30) per share for the year. Chardan Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. Chardan Capital also issued estimates for Xenon Pharmaceuticals’ FY2026 earnings at ($2.15) EPS.

Other equities analysts have also recently issued reports about the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Bloom Burton raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, October 7th. Wells Fargo & Company reiterated an “overweight” rating and issued a $44.00 price objective (down previously from $48.00) on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. JPMorgan Chase & Co. upped their price objective on shares of Xenon Pharmaceuticals from $57.00 to $60.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Finally, Wedbush lifted their price target on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the company an “outperform” rating in a research report on Tuesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $54.27.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $41.16 on Monday. The stock has a market capitalization of $3.18 billion, a PE ratio of -11.59 and a beta of 1.10. Xenon Pharmaceuticals has a one year low of $26.74 and a one year high of $44.23. The business’s fifty day moving average price is $39.81 and its 200-day moving average price is $35.65.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Monday, November 3rd. The biopharmaceutical company reported ($1.15) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.01. The business’s revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.81) EPS.

Institutional Trading of Xenon Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Driehaus Capital Management LLC increased its stake in shares of Xenon Pharmaceuticals by 1.4% in the first quarter. Driehaus Capital Management LLC now owns 4,584,859 shares of the biopharmaceutical company’s stock worth $153,822,000 after purchasing an additional 64,264 shares in the last quarter. Wellington Management Group LLP grew its position in Xenon Pharmaceuticals by 0.3% in the 1st quarter. Wellington Management Group LLP now owns 3,789,197 shares of the biopharmaceutical company’s stock valued at $127,128,000 after acquiring an additional 11,586 shares during the last quarter. Braidwell LP increased its stake in Xenon Pharmaceuticals by 33.0% in the 2nd quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock worth $112,837,000 after buying an additional 895,154 shares during the period. Commodore Capital LP raised its stake in shares of Xenon Pharmaceuticals by 30.1% during the second quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after acquiring an additional 700,000 shares in the last quarter. Finally, Vestal Point Capital LP lifted its stake in Xenon Pharmaceuticals by 53.8% in the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $62,600,000 after acquiring an additional 700,000 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insider Activity

In related news, CEO Ian Mortimer sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $40.16, for a total transaction of $1,004,000.00. Following the completion of the sale, the chief executive officer directly owned 31,302 shares in the company, valued at approximately $1,257,088.32. The trade was a 44.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.